[1] Chen W,Zheng R,Baade PD,et al. Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.DOI:10.3322/caac.21338.
[2] Wu M,Van′t VP,Zhang ZF,et al. A large proportion of esophageal cancer cases and the incidence difference between regions are attributable to lifestyle risk factors in China[J].Cancer Lett,2011,308(2):189-196.DOI:10.1016/j.canlet.2011.05.003.
[3] Herskovic A,Martz K,al-Sarraf M,et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus[J].N Engl J Med,1992.326(24):1593-1598. DOI:10.1056/NEJM199206113262403.
[4] Cooper JS,Guo MD,Herskovic A,et al. Chemoradiotherapy of locally advanced esophageal cancer:long-term follow-up of a prospective randomized trial (RTOG 85-01)[J].JAMA,1999,281(17):1623-1627.
[5] Wang H,Li G,Chen L,et al. Definitive concurrent chemoradiotherapy with S-1 and cisplatin in elderly esophageal squamous cell carcinoma patients[J].J Thorac Dis,2017,9(3):646-654.DOI:10.21037/jtd.2017.03.105.
[6] Servagi-Vernat S,Créhange G,Roullet B,et al. Phase Ⅱ study of a platinum-based adapted chemotherapy regimen combined with radiotherapy in patients 75 years and older with esophageal cancer[J].Drugs Aging,2015,32(6):487-493.DOI:10.1007/s40266-015-0275-8.
[7] Song T,Zhang X,Fang M,et al. Concurrent chemoradiotherapy using paclitaxel plus cisplatin in the treatment of elderly patients with esophageal cancer[J].Oncol Targ Ther,2015,8:3087-3094.DOI:10.2147/OTT.S92537.
[8] Semrau R,Herzog SL,Vallböhmer D,et al. Radiotherapy in elderly patients with inoperable esophageal cancer. Is there a benefit[J].Strahlenther Onkol,2012.188(3):226-232.DOI:10.1007/s00066-011-0039-2.
[9] Tougeron D,Di FF,Thureau S,et al. Safety and outcome of definitive chemoradiotherapy in elderly patients with oesophageal cancer[J].Br J Cancer,2008,99(10):1586-1592.DOI:10.1038/sj.bjc.6604749.
[10] Takeuchi S,Ohtsu A,Doi T,et al. A retrospective study of definitive chemoradiotherapy for elderly patients with esophageal cancer[J].Am J Clin Oncol,2007,30(6):607-611.DOI:10.1097/COC.0b013e3180ca7c84.
[11] Markar SR,Karthikesalingam A,Thrumurthy S,et al. Systematic review and pooled analysis assessing the association between elderly age and outcome following surgical resection of esophageal malignancy[J].Dis Esophagus,2013,26(3):250-262.DOI:10.1111/j.1442-2050.2012.01353.x.
[12] Fogh SE,Yu A,Kubicek GJ,et al. Do elderly patients experience increased perioperative or postoperative morbidity or mortality when given neoadjuvant chemoradiation before esophagectomy[J].Int J Radiat Oncol Biol Phys,2011,80(5):1372-1376.DOI:10.1016/j.ijrobp.2010.04.055.
[13] Lester SC,Lin SH,Chuong M,et al. A multi-institutional analysis of trimodality therapy for esophageal cancer in elderly patients[J].Int J Radiat Oncol Biol Phys,2017,98(4):820-828.DOI:10.1016/j.ijrobp.2017.02.021.
[14] Miyata H,Yamasaki M,Makino T,et al. Clinical outcome of esophagectomy in elderly patients with and without neoadjuvant therapy for thoracic esophageal cancer[J].Ann Surg Oncol,2015,22 Suppl 3:794-801.DOI:10.1245/s10434-015-4769-8.
[15] Kodama M,Kakegawa T.Treatment of superficial cancer of the esophagus:a summary of responses to a questionnaire on superficial cancer of the esophagus in Japan[J].Surgery,1998,123(4):432-439.
[16] Hölscher AH,Bollschweiler E,Schröder W,et al. Prognostic impact of upper,middle,and lower third mucosal or submucosal infiltration in early esophageal cancer[J].Ann Surg,2011,254(5):802-807,807-808.DOI:10.1097/SLA.0b013e3182369128.
[17] Molena D,Stem M,Blackford AL,et al. Esophageal cancer treatment is underutilized among elderly patients in the USA[J].J Gastroint Surg,2017,21(1):126-136.DOI:10.1007/s11605-016-3229-5.
[18] Moreno AC,Verma V,Hofstetter WL,et al. Patterns of care and treatment outcomes of elderly patients with stage Ⅰ esophageal cancer:analysis of the national cancer data base[J].J Thorac Oncol,2017,12(7):1152-1160.DOI:10.1016/j.jtho.2017.04.004.
[19] Jing W,Guo H,Kong L,et al. Clinical outcomes of elderly patients (≥70 years) with resectable esophageal squamous cell carcinoma who underwent esophagectomy or chemoradiotherapy:a retrospective analysis from a single cancer institute[J].Medicine (Baltimore),2016,95(50):e5630.DOI:10.1097/MD.0000000000005630.
[20] Smith GL,Smith BD,Buchholz TA,et al. Patterns of care and locoregional treatment outcomes in older esophageal cancer patients:the SEER-Medicare cohort[J].Int J Radiat Oncol Biol Phys,2009,74(2):482-489.DOI:10.1016/j.ijrobp.2008.08.046.
[21] Abrams JA,Buono DL,Strauss J,et al. Esophagectomy compared with chemoradiation for early stage esophageal cancer in the elderly[J].Cancer,2009,115(21):4924-4933.DOI:10.1016/j.ijrobp.2008.08.046.
[22] Xi M,Xu C,Liao Z,et al. The impact of histology on recurrence patterns in esophageal cancer treated with definitive chemoradiotherapy[J].Radiother Oncol,2017,124(2):318-324.DOI:10.1016/j.radonc.2017.06.019.
[23] Kelsen DP,Winter KA,Gunderson LL,et al. Long-term results of RTOG trial 8911(USA Intergroup 113):a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer[J].J Clin Oncol,2007,25(24):3719-3725.DOI:10.1200/JCO.2006.10.4760.
[24] Sjoquist KM,Burmeister BH,Smithers BM,et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma:an updated meta-analysis[J].Lancet Oncol,2011,12(7):681-692.DOI:10.1016/S1470-2045(11)70142-5.
[25] Cohen HJ,Feussner JR,Weinberger M,et al. A controlled trial of inpatient and outpatient geriatric evaluation and management[J].N Engl J Med,2002,346(12):905-912.DOI:10.1056/NEJMsa010285.
[26] Corre R,Greillier L,Le CH,et al. Use of a comprehensive geriatric assessment for the management of elderly patients with advanced non-small-cell lung cancer:the phase Ⅲ randomized ESOGIA-GFPC-GECP 08-02 study[J].J Clin Oncol,2016,34(13):1476-1483.DOI:10.1200/JCO.2015.63.5839.
[27] Caillet P,Canoui-Poitrine F,Vouriot J,et al. Comprehensive geriatric assessment in the decision-making process in elderly patients with cancer:ELCAPA study[J].J Clin Oncol,2011,29(27):3636-3642.DOI:10.1200/JCO.2010.31.0664.
[28] Bedenne L,Michel P,Bouché O,et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus:FFCD 9102[J].J Clin Oncol,2007,25(10):1160-8116.DOI:10.1200/JCO.2005.04.7118.
[29] Zhang W,Zhu H,Liu X,et al. Epidermal growth factor receptor is a prognosis predictor in patients with esophageal squamous cell carcinoma[J].Ann Thorac Surg,2014,98(2):513-519.DOI:10.1016/j.athoracsur.2014.03.015.
[30] Guo YM,Yu WW,Zhu M,et al. Clinicopathological and prognostic significance of epidermal growth factor receptor overexpression in patients with esophageal adenocarcinoma:a meta-analysis[J].Dis Esophagus,2015,28(8):750-756.DOI:10.1111/dote.12248.
[31] Ramos-Suzarte M,Lorenzo-Luaces P,Lazo NG,et al. Treatment of malignant,non-resectable,epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy[J].Cancer Biol Ther,2012,13(8):600-605.DOI:10.4161/cbt.19849.
[32] Liang J,E M,Wu G,et al. Nimotuzumab combined with radiotherapy for esophageal cancer:preliminary study of a Phase Ⅱ clinical trial[J].Onco Targets Ther,2013,6:1589-1596.DOI:10.2147/OTT.S50945.
[33] Lin SH,Zhang N,Godby J,et al. Radiation modality use and cardiopulmonary mortality risk in elderly patients with esophageal cancer[J].Cancer,2016,122(6):917-928.DOI:10.1002/cncr.29857.